All In Biotech

Drug Trial Radar · NCT03245190

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Efficacy and Safety of Chiauranib in Advanced Hepatocellular Carcinoma: a Single-arm, Open-label, Multi-center, Exploratory Phase Ib Study

Last checked: Nov 19, 2026Latest source record: Jun 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Apr 28, 2018

Primary completion

Nov 1, 2019

Study completion Nov 1, 2019

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Aug 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • ChiauranibDrug

    50mg, orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 16 weeks progression-free rate (16W-PFR)Time frame: Up to a minimum 16 weeks after the last participant's first dose, or progression, or died, whichever came first

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.